HERO

Adrian Hernandez, MD, MHS
HERO Research Program, Principal Investigator

“Healthcare workers who are on the front lines have the opportunity to help everyone understand the impact of the COVID-19 crisis on them and their colleagues, families, and friends. Signing up for this registry is yet another contribution they make.”

Adrian Hernandez, MD, MHS
HERO Research Program, Principal Investigator

Join the registry

Who is eligible?*
What is involved?*

13,264

Registry Participants Enrolled
5/27/20

Read the HERO Registry protocol.

HERO Invites Healthcare Workers to Fight COVID-19 Together

The Healthcare Worker Exposure Response & Outcomes (HERO) Registry is a large, national clinical research community. It invites healthcare workers across America to share clinical and life experiences to understand the perspectives and problems they face on the COVID-19 pandemic front lines.

HERO Registry participants could have the opportunity to participate in future research studies to improve our understanding of COVID-19 and beyond, generating evidence to help keep healthcare workers safe and healthy. The first study, the HERO-HCQ Trial, will invite 15,000 healthcare workers from the registry to evaluate whether hydroxychloroquine can prevent COVID-19 infections.

Who can Join?

The HERO Registry is open to all healthcare workers, including nurses, therapists, physicians, emergency responders, food service workers, environmental service workers, interpreters, transporters — anyone who works in a setting where people receive health care.

To join, participants must be:

  • A U.S. healthcare worker in any profession
  • ≥ 18 years old

You can use a work email address, gmail address, or another email address to sign up. Click here for easy step-by-step instructions.

JOIN

Why a Community of Healthcare Workers?

Healthcare workers are on the front lines fighting the COVID-19 infection. Healthcare workers are more at risk, both physically and mentally, of the toll the pandemic poses.

We need evidence to keep healthcare workers and their families safe and healthy, which ultimately will help protect us all. Their input will help us study and address the problems our healthcare heroes face in real time — and over time.

The HERO Registry community will be at the ready to facilitate rapid-cycle research starting with the HERO-HCQ Trial.

What Does Participation Involve?

There is no cost to join and it takes only a few minutes to sign up. You can use a work email address, gmail address, or another email address.

After joining, you will receive surveys, opportunities to participate in future studies, and learnings from the HERO research community.

We will gather information such as where you work and what you do, along with your interests in fighting COVID-19 by joining clinical research studies. Next, we will ask questions about your COVID-19 experiences so we can address them as a community. After that, we will follow-up to ask what’s needed next to address healthcare worker needs. As a HERO Registry participant, you will have the opportunity to help us identify needs and issues that are most important to address – your input will be critical in prioritizing registry activities.  Along the way, we will share what we learn in HERO to fight the pandemic and improve the health and well-being of healthcare workers.

Together, our healthcare heroes can ENGAGE to help find answers that will PROTECT and IMPROVE the health and well-being of America’s front line.

Acknowledgements

The HERO research program is funded through a Patient-Centered Outcomes Research Institute Award (Contract Number: COVID-19-2020-001). The program is coordinated by the Duke Clinical Research Institute and leverages PCORnet®, the National Patient-Centered Clinical Research Network.

The HERO research program is made possible by contributions and services from other organizations, including:

  • Almac Group, for drug distribution and randomization services
  • Covance, for central lab coordination and testing
  • Sandoz, the Novartis generics and biosimilars division, for the donated study medication and matching placebo
  • Verily Life Sciences, for software and technology to support the participant portal and secure data platform